FDA Halts Rocket Pharma's Gene Therapy Trial After Patient Death
TL;DR Summary
A patient died following an experimental gene therapy trial by Rocket Pharmaceuticals for Danon disease, prompting the FDA to halt the study and investigate the cause, with concerns centered around a novel immune suppression agent used in the treatment regimen.
Topics:business#clinical-trial#danon-disease#gene-therapy#health#patient-death#rocket-pharmaceuticals
- Patient dies in trial of Rocket gene therapy for heart condition BioPharma Dive
- FDA halts Rocket Pharma's gene therapy trial as patient dies Reuters
- Gene Therapy Death Worsens Picture for an Already Troubled Field Barron's
- Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Business Wire
- Rocket crashes as gene therapy patient dies, FDA imposes hold Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 3 min read
Condensed
93%
543 → 40 words
Want the full story? Read the original article
Read on BioPharma Dive